🇺🇸 FDA
Patent

US 9173947

Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom

granted A61KA61K47/24A61K47/548

Quick answer

US patent 9173947 (Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom) held by Nektar Therapeutics expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K47/24, A61K47/548, A61K47/58, A61K47/60